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Background: A population reference database of complete human mitochondrial genome (mtGenome) sequences
is needed to enable the use of mitochondrial DNA (mtDNA) coding region data in forensic casework applications.
However, the development of entire mtGenome haplotypes to forensic data quality standards is difficult and
laborious. A Sanger-based amplification and sequencing strategy that is designed for automated processing, yet
routinely produces high quality sequences, is needed to facilitate high-volume production of these mtGenome
data sets.
Results: We developed a robust 8-amplicon Sanger sequencing strategy that regularly produces complete,
forensic-quality mtGenome haplotypes in the first pass of data generation. The protocol works equally well on
samples representing diverse mtDNA haplogroups and DNA input quantities ranging from 50 pg to 1 ng, and
can be applied to specimens of varying DNA quality. The complete workflow was specifically designed for
implementation on robotic instrumentation, which increases throughput and reduces both the opportunities for error
inherent to manual processing and the cost of generating full mtGenome sequences.
Conclusions: The described strategy will assist efforts to generate complete mtGenome haplotypes which meet the
highest data quality expectations for forensic genetic and other applications. Additionally, high-quality data produced
using this protocol can be used to assess mtDNA data developed using newer technologies and chemistries.
Further, the amplification strategy can be used to enrich for mtDNA as a first step in sample preparation for
targeted next-generation sequencing.Background
Sequencing of human mitochondrial DNA (mtDNA) is
performed for a number of purposes in medical, anthropo-
logical, population and forensic genetics. In forensics,
mtDNA typing is most commonly employed when the
nuclear DNA in an evidentiary sample is too limited or too
damaged to develop sufficient nuclear data for forensic
comparisons. In this application, mtDNA sequencing has
historically been limited to the non-coding control region
(CR) or portions thereof, where the high concentration of
fast-mutating sites presents the greatest opportunity for
differentiation of samples representing distinct maternal
lineages while minimizing data generation costs and effort.
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stated.developed that interrogate portions of the mtDNA coding
region (codR) to resolve maternal lineages which cannot
be distinguished by CR typing alone ([1-4], for example),
and a very few commercial products are available for the
generation of data from the codR. However, the existence
of these methods has not yet translated into regular devel-
opment of mtDNA codR data in most forensic laboratories.
The in-house assays developed by various groups are not
commercialized, and thus quality control of primers and
reagents represents a substantial barrier to implementation;
and the commercially-available products are not well-suited
for typing the low DNA quantity evidentiary specimens to
which forensic mtDNA methods are typically applied [5,6].
Next-generation sequencing technologies may eventually
facilitate development of complete mitochondrial genome
(mtGenome) data from even very poor quality forensic
specimens [7,8]. Yet, before any of these assays and tech-
nologies can be routinely applied in forensic casework,
complete mtGenome population reference data developedtd. This is an Open Access article distributed under the terms of the Creative
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http://www.biomedcentral.com/1471-2164/14/881to forensic standards must be on hand to permit generation
of the haplotype frequency estimates required for likelihood
calculations [5]. At present, no such data is publicly
available.
The generation of entire mtGenome haplotypes from
even pristine quality and high DNA quantity samples by
Sanger sequencing is generally expensive and laborious.
A large number of individual sequences are required
for sufficient high-resolution coverage across the entire
approximately 16.5 kilobase molecule, and past analyses
of published mtGenome data sets have identified various
errors [9,10]. And while next-generation sequencing tech-
nologies are likely to facilitate the development of entire
mtGenome data sets, the fact that these methods have not
yet been fully vetted and validated for forensic use means
that Sanger-based protocols currently remain the only
accepted method for the development of complete mtGe-
nome reference data that meet forensic data quality
standards [11]. A recently published manual sequencing
strategy generates high-quality Sanger sequence data with
redundant coverage across the mtDNA codR, and is
perfectly suitable for the development of mtGenome
reference data when combined with CR sequencing [12].
Yet to ease the way for more rapid, high-volume generation
of the complete mtGenome population reference data
needed for forensics, accommodate different sample sub-
strates and thus variable DNA quality/quantity, and further
decrease the opportunities for human error inherent in
manual sample handling, an entire mtGenome sequencing
protocol and workflow designed specifically for automated,
high-throughput processing is necessary.
To address this need, our aim was to devise a robust
amplification and Sanger sequencing strategy that could
be used for high-throughput production of complete
mtGenome haplotypes which meet the highest data
quality expectations while accommodating a wide range
of DNA quality and quantity. We report here on the
development of an 8-amplicon, 135-sequence mtGenome
data generation protocol that was specifically designed
to be performed in 96-well format and implemented
on robotic liquid handling instruments. The strategy
produces redundant sequence coverage across the entire
mtGenome in the first pass of automated data generation,
and generates high-quality sequences from a range of DNA




Amplification of the full mtGenome in eight fragments
was targeted to facilitate sample processing in 96-well
plate format, a strategy that permits eleven samples (plus
the appropriate negative controls) to be PCR-amplified
simultaneously (Figure 1). An established primer set whichamplifies the complete CR in an 1198 base pair (bp)
fragment [13] was utilized, and the development of seven
new overlapping amplicons to span the codR is described
below.
Given the need for a robust mtGenome assay that could
be applied with equal efficacy across samples representing
diverse mtDNA haplogroups, the potential for primer
binding site mutations was given careful consideration
in the design of codR amplification primers. To this end, a
“global alignment” developed from 193 complete or codR
only mtDNA sequences was used to assess regions of
the mtGenome appropriate for primer placement. The
alignment consisted of mtGenome sequences from most
major named mtDNA haplogroups (six sequences each
from haplogroups A, B, C, D, E, F, G, H, I, J, K, L0, L1, L2,
L3, L4, L5, M, N, P, Q, R, R0, S, T, U, V, W, X, Y, and Z;
and four and three sequences from haplogroups L6 and O,
respectively) sampled at random using GenBank accession
numbers available on the PhyloTree mtDNA phylogeny
[14]. In addition, published mtGenome substitution rate
data drawn from 2196 complete mtGenomes [15] were
used to develop a substitution rate histogram by nucleotide
position (not shown). In combination, the global alignment
and substitution rate graph were used to identify hap-
logroup-specific mutations and overall highly polymorphic
positions and/or regions which could potentially interfere
with proper primer annealing during PCR.
Initially, twenty-two codR amplification primers employed
for earlier mtGenome sequencing at our laboratory [16-20]
were evaluated for use in the new protocol. The global
alignment and substitution rate histogram described above
were used to assess the potential for primer binding site
mutations, and the web-based Primer3 program [21] was
used to examine primer characteristics such as melting
temperature, GC content, and self-complementarity. Based
on the criteria applied all previously used primers were
disqualified from further use, most due to potential primer
binding site issues. This is not indicative of poor design,
but rather reflects the enormous increase in the number
of mtGenome sequences available and our general under-
standing of mtDNA diversity today in comparison to
the late 1990s when the prior amplification strategy
was initially developed.
Seven new codR amplicons were designed using the
global alignment and substitution rate histogram. Within
bp ranges deemed acceptable (by virtue of a high degree
of sequence conservation, a lack of haplogroup-defining
mutations, and sufficient overlap with neighboring ampli-
cons), specific primer sequences were selected using the
default settings in Primer3 [21]. Amplification primer
sequences are given in Table 1. The average overlap between
amplicons is 210 bp, with a minimum overlap of 71 bp
(between Amplicons 7 and 8) and a maximum overlap
of 338 bp.
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Figure 1 Amplification plate layout. Plate map for simultaneous amplification of eleven samples in a 96-well plate. Samples are organized by
columns (Sample 1 in column 1, Sample 2 in column 2, etc.), and each row represents one of the eight mtGenome amplicons (Amplicon 1 in
row 1, Amplicon 2 in row 2, etc.). Negative controls for each target fragment are amplified in column 12.
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the mtGenome sequencing strategy were 1) the desire to
develop high-resolution sequence coverage in both the
forward and reverse directions across as much of the
molecule as feasible, and 2) a protocol that would be
amenable to high-throughput processing on automated
liquid-handling instrumentation. For the CR, the sequencing
approach described by [13] was adopted. CodR primers
previously utilized by our laboratory for mtGenome se-
quencing [16-20] were evaluated using the global align-
ment, substitution rate histogram, and Primer3 software
[21], as described above. In addition, the typical quality
of the sequence data produced by seventy-four of these
primers was assessed by inspection of 2237 previously-
generated sequence electropherograms, and only primers
which routinely produced data with sufficient signal and
minimal noise were considered for further use. As a result
of these examinations, twenty sequencing primers were
maintained for use in the new protocol. Ninety-nine new
primers were selected in the same manner as described
above for the amplification primers, with old and new
codR sequencing primers spaced at intervals designed to
produce overlapping, high-resolution forward and reverse
sequence coverage across the genome.
The final, 8-amplicon mtGenome strategy is depicted in
Figures 2 and 3. The number of sequencing primers per
amplicon ranges from sixteen to eighteen, and the strategy
produces 135 sequences from 127 unique primers. The
resulting redundant sequence coverage across the complete
mtGenome is demonstrated in Figure 4. Sequencing
primers and their sources (published or new) are listedin Table 3. Thermal cycling conditions implemented for
PCR and sequencing are identical to those previously
described for complete mtGenome sequencing [16-20],
with one exception: as the coding region amplicons in this
assay range in size from 2208 to 2759 bp, a 2.5 minute
extension time was selected to balance PCR product
generation and total thermal cycling time. Thermal cycling
details are included in the Methods section.
All steps of the mtGenome protocol described here
were designed with high-throughput applications in mind.
To this end, plate layouts and programs which permit effi-
cient sample handling and reaction set-up on robotic in-
strumentation were developed to facilitate highly
automated data generation. Details of our high-
throughput process, including plate maps and strategies
for amplification, sequencing, and purification steps, are
covered in the Methods section.
Sensitivity testing
To assess the sensitivity of the amplification protocol,
PCR was performed in duplicate for a range of positive
control (Human Cell Line DNA 9947A; Life Technologies,
Gibco, Carlsbad, CA) DNA input quantities (300 pg, 100
pg, 25 pg, 10 pg, 5 pg, 2.5 pg, 1.0 pg, 0.5 pg 0.25 pg, and
0.1 pg). The PCR products were quantified using the
QIAxcel Advanced system (QIAGEN Inc., Valencia, CA)
and the resulting values were normalized with respect to
amplicon size to enable direct comparison. Figure 5
displays a box and whisker plot of the normalized amplifi-
cation product concentrations, reported here in ng/μL per
1000 bp, at each DNA input concentration. The long
Table 1 Amplification primers
Amplicon number Amplicon size Primer name Primer sequence Source
1 2417 F402 ATCTTTTGGCGGTATGCACTTT New
R2818 GCCCCAACCGAAATTTTTAAT New
2 2381 F2480 AAATCTTACCCCGCCTGTTT New
R4860 GAAGAAGCAGGCCGGATGT New
3 2291 F4609 AAATAAACCCTCGTTCCACAGA New
R6899 CATATTGCTTCCGTGGAGTGTG New
4 2511 F6636 ATTCTTATCCTACCAGGCTTCG New
R9146 GCGACAGCGATTTCTAGGATAG New
5 2489 F8940 CCCCATACTAGTTATTATCGAAACC New
R11428 GGCTTCGACATGGGCTTT New
6 2759 F11319 CAAACTCCTGAGCCAACAACTT New
R14077 TTTGGGTTGAGGTGATGATG New
7 2208 F13835 CAGCCCTAGACCTCAACTACC New
R16042 CTGCTTCCCCATGAAAGAAC [19]
8 1198 F15971 TTAACTCCACCATTAGCACC [13]
R599 TTGAGGAGGTAAGCTACATA [13]
Amplification primer sequences for the eight mtGenome amplicons. The primers for Amplicon 8, which covers the mtDNA CR, were adopted from [13]. The
reverse primer for Amplicon 7 (R16042) was previously designed for use as a sequencing primer [19]. All primers except F2480 (Amplicon 2), R4860 (Amplicon 2),
R9146 (Amplicon 4) and R14077 (Amplicon 6) are also used for sequencing (see Table 2).
T2
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DNA input level reflect the range of sensitivities of the
eight primer pairs, however all regions were successfully
amplified down to 10 pg of input DNA. Beginning at 5 pg
input DNA a few amplification failures were observed,
and below 1 pg input successful amplification was sporadic
and limited to a few high-efficiency primer pairs.Developmental validation on population samples
To evaluate the performance of the protocol on a variety
of haplotypes, eleven anonymous, high-quality population
samples from ten distinct mtDNA haplogroups (A, B, C,
D, H, U, K, L1, L2 and L3) were amplified in duplicate and
sequenced using the automated, high-throughput process
described in the Methods section. The DNA input for
PCR varied by sample, and ranged from approximately
0.1-1.5 ng. Trimming and assembly of the raw electrophe-
rograms for replicate samples was performed by separate
individuals according to laboratory standard guidelines for
data quality in terms of background to noise ratio and
peak resolution. Sequence coverage across the molecule
was assessed in terms of a) redundant and bi-directional
coverage, b) the degree of additional manual re-processing
that would be required to develop complete replicate
coverage, and c) the correlation between sequence cover-
age and sequence distance from the revised Cambridge
Reference Sequence (rCRS) [22]. The final haplotypes
for each sample were compared to control data (complete
mtGenome profiles previously developed from the same
sample extracts [20]).High quality sequence data (as defined by signal to
noise ratio) was developed from most primers for most
samples in a single pass with the automated system. As
Figure 6 depicts, on average 99.87% (SD = 0.23%) of the
mtGenome was covered by at least 2 sequences, and
99.07% (SD = 0.67%) of the mtGenome had both forward
and reverse sequence coverage when small regions with
unidirectional coverage due to length heteroplasmy in
hypervariable regions 1 and 2 were ignored. The number
of manual resequencing reactions that would be required
to achieve redundant coverage ranged from zero to two
(Figure 7), with approximately one resequencing reaction
required for every two complete haplotypes. Considering
that 135 sequences were generated for each sample,
this equates to a 0.32% resequencing rate. A weak but
non-significant correlation was observed between mtGe-
nome coverage and sequence distance from the rCRS,
with a mere 1-3% of the variance in mtGenome coverage
attributed to sequence distance (data not shown). In all
cases the final haplotype matched the haplotype previously
developed for each sample.
Potential for NUMT amplification
Though amplification of nuclear insertions of mitochon-
drial DNA (NUMTs) is unlikely when sufficient mtDNA
is present in a sample [23], the reference assembly of the
complete human genome was nonetheless queried using
PrimerBLAST [24] for the seven codR amplification
primer pairs. Any close sequence matches (defined as
75% or greater overall similarity for both primers, with
no more than one mismatch in the 3′ most 5 bp) that
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Sequencing primers for the complete mtGenome, with sources
(new or previously published). All primers for Amplicon 8, which
covers the mtDNA CR, were adopted from [13]; these are used in
duplicate to produce a total of sixteen sequences for the CR. Most
amplification primers are also utilized as sequencing primers
(see Table 1).
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the authentic mitochondrial target (less than 500 bp
difference) were further evaluated. For each potentially
amplifiable nuclear genome region, the percentage
similarity to modern mtDNA was assessed by aligning
the NCBI reference sequence to the rCRS in Sequencher
version 4.8 (Gene Codes Corporation, Ann Arbor, MI).
When the nuclear genome sequence region could not be
aligned to the rCRS due to high dissimilarity, the percent-
age similarity was noted as being less than 60%.Using the described criteria, thirteen potentially ampli-
fiable regions of the nuclear genome were identified
(Table 3). Of these, only three had a sequence similarity to
the rCRS greater than 90%. For the two Chromosome 1
regions with greater than 98% sequence similarity to
Amplicon 3 (2291 bp) and Amplicon 4 (2511 bp), the
Chromosome 1 sequence differed from the rCRS sequence
at thirty-five and thirty-six nucleotide positions, re-
spectively. This region in Chromosome 1 corresponds
to a described NUMT approximately 5842 bp in length
[25]. No NUMT amplification was observed during
protocol development or developmental validation.Sequencing artifacts
Sequencing artifacts (i.e. small regions of compression
and/or unusual peak morphology) due to region-specific
sequence motifs were reproducibly observed in both the
positive control samples sequenced during protocol devel-
opment and the developmental validation on population
samples. Typically, each artifact was observed in a single
sequence direction, and the severity of the artifact varied
by primer distance from the artifact. An example of a
sequencing artifact is shown in Figure 8.
The standard sequencing protocol used at our laboratory
for high-throughput generation of mtDNA population data
includes one-quarter the recommended volume of BigDye®
Terminator v1.1 Ready Reaction Mix (Life Technologies,
Applied Biosystems, Foster City, CA) and replaces 25%
of the dITP-containing BigDye® with dGTP BigDye®
Terminator v1.1 Ready Reaction Mix ([19]; reaction vol-
umes are specified in the Methods section). The addition
of dGTP BigDye® was originally implemented to assist the
sequencing of difficult templates, specifically GC-rich
regions or polycytosine tracts, in the reverse direction.
For this protocol, dGTP BigDye® was eliminated from
forward sequencing reactions to reduce the number of
artifacts produced in those sequences (Figure 8). All
remaining artifacts (nearly all of which occurred in the
reverse direction) that were consistent and reproducible
across multiple samples, and with replicate sequencing,
were cataloged. In practice in our laboratory, this catalog
is referenced during assembly and analysis of mtGenome
sequences, and known artifacts are annotated in the
assembled contig.
It is worth noting here that these types of sequencing
artifacts are typically only apparent and recognizable as
such because the quality of the sequence data produced
is generally pristine. With even a small amount of noise
in the sequence data, many of these artifacts would not
be evident. In general, the artifacts do not confound data
interpretation, as they are typically minor and apparent
in only one sequencing direction. Nevertheless, when



















Figure 2 Amplification of the mtGenome in eight fragments. Positioning of the eight, overlapping target fragments around the circular
mtGenome, along with the primers used to amplify each region, is depicted.
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as ambiguous and resequence the region to confirm that
the authentic sequence is represented in the consensus
sequence for the region.
Discussion
Though the mtGenome amplification and sequencing
protocol we have developed can be performed manually
(with, we must emphasize, abundant attention paid at
pipetting steps to prevent sample misplacement), the
strategy was specifically designed to be implemented on li-
quid handling instruments to facilitate high-throughput
data generation. In our laboratory, all pre-PCR pipetting
steps (including sample placement, extraction and PCR
reaction set-up) are performed in 96-well plate format on
a benchtop liquid handling robot; amplification product
detection is performed directly from the 96-well plate
on a capillary electrophoresis instrument; and, with the
exception of the addition of enzymes for post-PCR
purification (which, due to high viscosity, are pipetted
manually into the sample plate to reduce reagent waste
and cost), all post-PCR pipetting steps are performed
robotically. The particulars of our automated sample
processing workflow are detailed in the Methods section.
The high-throughput strategy described here is presently
being employed in our laboratory to develop complete
mtGenome haplotypes from anonymous blood serum
specimens for a National Institute of Justice funded
reference population databasing project. Thoughfrequently used for cancer biomarker detection, blood
serum is a challenging source for forensic DNA typing as
the only DNA present in these samples is residual [26].
Using a silica column based extraction protocol, DNA
concentrations (measured using an mtDNA quantitative
PCR assay) for a set of 242 blood serum extracts averaged
just 15 pg/μL. When those extracts were amplified for the
mtGenome, PCR success was strongly dependent on input
DNA quantity. Overall, however, the amplification results
were consistent with those obtained during sensitivity
testing of this protocol, where amplification failures
were observed at DNA inputs below 10 pg (see Figure 5).
With the blood serum specimens typed using this
protocol for the databasing effort, 86.6% of all amplifica-
tion failures occurred when PCR inputs were less than 10
pg; and at DNA input quantities equal to or greater than
10 pg, 99.4% of amplifications were successful (data not
shown).
Based on the observation of some PCR failures with
positive control DNA (this paper) and blood serum extracts
when DNA concentrations were low, and given the extent
of sample reprocessing necessary at various PCR input
DNA quantities with the blood serum specimens, we
suggest an input DNA concentration for PCR of 50 pg
or greater when possible. Further, due to the increased
noise (a result of excessive electrophoretic signal) observed
in some sequences during the development of this protocol
when DNA inputs for PCR were high (data not shown), we












































































































































Figure 3 Organization of sequencing primers by amplicon. Approximate positioning and coverage of each of the 127 sequencing primers
used to generate 135 sequences across the mtGenome. Amplicon start and end points (in terms of nucleotide position) are given, and forward
sequences are represented above the template strand while reverse sequences are listed below. The number of sequencing primers per
amplicon ranges from sixteen to eighteen. The sequencing strategy used for the CR (Amplicon 8) was adopted wholesale from [13] and uses
eight distinct primers to produce sixteen sequences.
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high quality data has been developed from higher and
substantially lower DNA inputs using this protocol, inputs
between 50 pg and 1 ng should ensure consistent amplifica-
tion success and the production of high-quality sequence
data across all amplicons in the first pass of sample process-
ing. Following these DNA input guidelines will accordingly
reduce the opportunities for human error inherent in
manual sample reprocessing and minimize the cost to
generate each mtGenome haplotype.
Regarding the potential for amplification of portions of
the human nuclear genome (covered in the Results section
and summarized in Table 3), it seems highly improbablethat a NUMT sequence would be represented in a com-
pleted mtGenome haplotype developed using this protocol.
Amplification of a nuclear genome sequence alone (in
place of the target mtDNA) is extremely unlikely given
the abundance of mtDNA relative to nuclear DNA in
human cells, and could reasonably only be expected to
occur if mtDNA were nearly or completely absent in a
DNA extract [23]. In the unlikely case that a NUMT
were amplified in place of the mtDNA target, any close
inspection of the data (which would reveal an excess
number of differences from the rCRS; unusual insertions,
deletions, and/or transversions; etc.) or attempt to assign
a haplogroup to the mtGenome profile would readily
*** * *
Figure 4 mtGenome sequence coverage. This Sequencher (Gene Codes Corporation) screen capture demonstrates the typical mtGenome
sequence coverage that results from the 135-sequence strategy. Individual forward sequences are denoted in green, and reverse sequences are
represented in red. The data come from a population sample processed for the project described in [26], and no reprocessing was required to
achieve complete coverage across the mtGenome. Small regions with replicate but unidirectional coverage (three in the CR due to polycytosine
stretches and length heteroplasmy, and two in the codR, totaling 294 bp) are indicated by blue hashing in the coverage bar and asterisks.
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overall low DNA quantity sample is co-amplification of a
NUMT with the authentic mtDNA, which could occur
when by chance the mtDNA primers encounter a
close-match nuclear DNA target during the early cycles of
PCR. While we did not encounter this during protocol
development, it is possible that it may be observed as
more samples – and particularly those with extremely low
DNA template quantities – are processed with this assay.
However, if NUMT co-amplification were to happen, it
would a) likely occur with only one of the eight mtGe-
nome amplicons at a time, and b) present as a clear
mixture in the sequence data for that amplicon, as the
high number of positions at which two bases would be
observed could not reasonably be explained by mtDNA
heteroplasmy.
In addition to a robust laboratory protocol and, pref-
erably, automated rather than manual sample processing,
a well-considered data analysis workflow that includes
proper procedures for data interpretation and handling is
essential to the generation of high quality, error-free
mtDNA data for forensic genetic or other purposes. For
the development of complete mtGenome haplotypes we
recommend adoption of the best practice alignment,
nomenclature and reporting guidelines outlined for the
production of mtDNA CR data for forensics [27-29].
We also recommend review of the raw electropherogramdata by at least two scientists and fully electronic data
transfer, as described in [13,30]. Further, with the use
of a multi-amplicon protocol such as the one presented
here, and especially if any manual processing must be
performed, we suggest additional post-data production
checks to confirm that each complete mtGenome haplo-
type represents data from a single sample.Conclusion
We have developed a high-throughput amplification and
sequencing strategy that regularly produces redundant
sequence coverage across the entire mtGenome in the
first pass of automated data generation. The described
workflow, especially when implemented on robotic instru-
mentation, reduces both the cost of mtGenome sequen-
cing and the opportunities for human error by decreasing
the extent of manual sample processing/reprocessing
required. As the amplification and sequencing primers
were carefully selected based on highly conserved regions
of the mtGenome, the protocol works equally well on
samples originating from diverse mtDNA haplogroups,
yet minimizes the opportunity for non-specific binding
that could result in NUMT amplification. DNA input
quantities between 50 pg and 1 ng are recommended
to maximize first-pass data production success, how-
ever high-quality data and complete mtGenome


















1 1 Chr 11 (9510471–9507925) NT_009237.18 76.2%; 76.2% 170 < 60%
2 1 Chr 6 (53426379–53424135) NT_025741.15 84.2%; 78.9% 118 < 60%
3 1 Chr 1 (43791–46082) NT_004350.19 100%; 100% 1 98.47%
4 2 Chr 1 (45818–48327) NT_004350.19 95.5%; 100% 1 98.57%
Chr 5 (7704044–7701575) NT_034772.6 95.5%; 90.9% 1 88.53%
5 2 Chr 7 (6847950–6850445) NT_033968.6 84.0%; 88.9% 7 75.16%
Chr 2 (10717704–10720523) NT_022135.16 80.0%; 88.9% 331 63.40%
6 2 Chr 5 (42577018–42574300) NT_034772.6 95.5%; 100% 0 94.02%
Chr 5 (7699358–7696640) NT_034772.6 90.5%; 90.0% 0 88.97%
7 4 Chr 5 (2218206–2220412) NT_034772.6 95.2%; 90.0% 1 87.27%
Chr 5 (2218173–2220412) NT_034772.6 81.0%; 90.0% 32 87.19%
Chr 17 (13111672–13109937) NT_010718.16 80.0%; 85.0% 453 < 60%
Chr 7 (5831689–5829543) NT_033968.6 81.0%; 75.0% 41 < 60%
CodR amplification primer pairs were queried against the reference assembly of the complete human genome using PrimerBLAST [24], and results which met
specific similarity criteria were noted. For these thirteen regions of the nuclear genome which are potentially amplifiable using the codR PCR primer pairs listed in
Table 1, the nuclear genome sequence was aligned to the rCRS [22] to determine a percentage sequence similarity. The two Chromosome 5 matches listed for
Amplicon 7 represent slightly different primer binding sites within the same portion of the chromosome.
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DNA quantities.
This strategy should facilitate more rapid production
of the complete mtGenome population reference data
needed for future forensic applications, and, when com-




































Figure 5 Amplification sensitivity with positive control DNA. Results fr
input levels of positive control DNA (9947A). Amplification product concen
injection on a QIAxcel Advanced capillary electrophoresis instrument (QIAG
variable sizes of the eight target fragments). The wide range of product co
amplification efficiencies of the eight primer pairs; however, PCR product wand interpretation strategies, ensure that the data sets
are of the highest quality possible. In addition, high-
quality data developed using this protocol can be utilized
comparatively to evaluate mtDNA data produced using
various next-generation sequencing chemistries and
platforms, an essential first step on the path to eventual2.5 pg 1 pg 0.5 pg 0.25 pg 0.1 pg
A Input
om duplicate amplifications of all eight mtGenome fragments with ten
trations of the target fragments were measured by automated
EN Inc.), and were normalized to ng/μL per 1000 bp (given the
ncentrations represented in the long “whiskers” reflects the differing

























Region and Sequence Coverage Type
Figure 6 Sequence coverage. Percentage of the codR or full mtGenome with redundant sequence coverage following a single pass of
automated data generation for eleven population samples, representing a range of mtDNA haplogroups, processed in duplicate. One sample, for
which all sequence data in a single direction for a single amplicon was unusable and sourced to instrument failure, was removed from the analysis as
an outlier; and small regions of unidirectional sequence coverage due to length heteroplasmy in hypervariable regions one and two in some samples
were ignored. On average across the twenty-two samples, high-quality forward and reverse coverage was produced for 99% of the mtGenome.
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Finally, the amplification portion of the assay also has
clear application as a straight-forward method to enrich




PCR (using the primers listed in Table 1) is performed





























(from smallest to larg
Figure 7 Reprocessing required. The number of manual resequencing re
coverage for the twenty-two population samples (duplicate processing of e
approximately one resequencing reaction for every two mtGenomes proce
not included in the analysis due sequence failures resulting from instrumen10X PCR Buffer I (Life Technologies, Applied Biosystems),
4 μL GeneAmp® dNTP blend 10 mM (Life Technologies,
Applied Biosystems), 2 μL of each 10 μM amplification
primer, 3 μL DNA extract, 0.5 μL (2.5 units) AmpliTaq
Gold® DNA Polymerase (Life Technologies, Applied
Biosystems), and 33.5 μL deionized water. Thermal cycling
conditions are: 96°C hold for 10 minutes; 40 cycles of 94°C
for 15 seconds, 56°C for 30 seconds, 72°C for 2.5 minutes;
and a 72°C hold for 7 minutes. A 96-well plate layout
for the simultaneous amplification of eleven samplesReplicate 1
Replicate 2
 Haplogroups
est distance from the rCRS)
actions that would be required to achieve complete double stranded
leven distinct samples) ranged from zero to two. This equates to
ssed. Replicate 1 of the sample representing haplogroup L2a1e1 was
t failure.
A B
Figure 8 Sequencing artifacts. A) Screen captures of forward sequences aligned in Sequencher (Gene Codes Corporation) showing compression
and unusual peak morphology around nucleotide position 7600. B) When the same primer (F7366) was used without the addition of dGTP BigDye®
(Life Technologies, Applied Biosystems), the sequencing artifacts were no longer apparent.
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Figure 1.
High-throughput amplification of the mtGenome in our
laboratory is performed on a liquid-handling instrument
(MICROLAB® STARlet, Hamilton Robotics, Reno, NV),
utilizing single-use, pre-made tubes of amplification master
mix (containing all amplification reagents except enzyme)
for each amplicon. The use of pre-made master mixes
streamlines the process of amplification set-up for a full
96-well plate, reduces the number of re-amplifications
required due to pipetting errors, limits the number of
potential causes when an amplification failure occurs, and
minimizes the number of freeze-thaw cycles for reagents
and primers. For our applications, an amplification master1 2 3 4 5 6
A F402 F619 F900 F1320 F1657 F1983
B F2625 F2932 F3241 F3441 F3635 F3890
C F4609 F4925 F5150 F5318 F5664 F5858
D F6636 F7075 F7366 F7527 F7821 F8129
E F8940 F9272 F9483 F9832 F10267 F10419
F F11319 F11760 F11964 F12194 F12452 F12741
G F13835 F14058 F14431 F14641 F14881 F15190
H F15971a F15971b F16190a F16190b F155a F155b
1 2 3 4 5 6
A R878 R1136 R1365 R1769 R1924 R2216
B R3006 R3417 R3825 R4162 R4479
C R5034 R5210 R5325 R5681 R5799 R5994
D R7248 R7489 R7766 R8141 R8378 R8640
E R9376 R9611 R9853 R10171 R10294 R10715
F R11768 R12089 R12302 R12766 R13025 R13390
G R14118 R14448 R14721 R14902 R15396 R15585
H R16410a R16410b R285a R285b R484a R484b
A
B
Figure 9 Forward and reverse primer plate maps for high-throughpu
reverse (B) sequencing primer plates. Primer plates are prepared roboticallymix is prepared in a 15 mL conical tube using 850 μL
GeneAmp® 10X PCR Buffer I (Life Technologies, Applied
Biosystems), 680 μL GeneAmp® dNTP blend 10 mM (Life
Technologies, Applied Biosystems), 340 μL of each 10 μM
amplification primer, and 5695 μL deionized water. Then,
744 μL is aliquoted to each of ten labeled 1.7 mL tubes and
stored at −20°C. Just prior to PCR reaction set-up, 8 μL (40
units) AmpliTaq Gold® DNA Polymerase (Life Technolo-
gies, Applied Biosystems) is added to the defrosted tube of
master mix.
With our semi-automated process, amplification success
is assessed by capillary electrophoresis. PCR products are
injected directly from the 96-well amplification plate on a


















t processing. 96-well plate layouts for single-use forward (A) and
to contain 50 μL of each 10 μM primer.
A B
Figure 10 Sequencing plate maps for high-throughput processing. 96-well plate layouts for sequencing eleven complete mtGenomes in
two sets (forward, A; and reverse, B), for a total of sixteen sequencing plates per eleven mtGenomes. The eleven different samples are indicated
by Ind1, Ind2, etc. and are color-coded, and the primer for each plate well is listed. Empty wells are noted. These plate layouts represent one strat-
egy for high-throughput sequencing, and were specifically designed for efficient pipetting on our laboratory’s liquid handling instruments
(MICROLAB® STARlet and STARplus, Hamilton Robotics). A different layout may be more appropriate/more efficient with other instrumentation.
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marker 50 bp/5 kb and the QX DNA size marker
250 bp-4 kb (QIAGEN Inc.). Alternatively, confirmation
that the correct size PCR products were generated could
be obtained by gel electrophoresis or another method.PCR product purification
Purification of amplification products prior to sequencing
is performed enzymatically, using 10 μL Exonuclease I
and 5 μL recombinant Shrimp Alkaline Phosphotase
(Affymetrix, USB, Cleveland, OH) per 50 μL PCR product.
For purification of a full 96-well plate of samples, a master
mix of 1100 μL Exonuclease I and 550 μL recombinant
Shrimp Alkaline Phosphotase is prepared, and 15 μL ofthe master mix is manually pipetted to each sample PCR
product. Negative controls in column 12 of the 96-well
plate are not purified. Thermal cycling conditions are 37°C
for 20 minutes followed by 90°C for 20 minutes.Sanger sequencing
Each mtGenome is sequenced in a total of 135 reactions
using 127 unique primers. The sequencing primers used
for each of the eight mtGenome amplicons are listed in
Table 2. Sequencing reactions include 8 μL deionized
water; 6 μL dilution buffer (400 mmol/l TRIS, 10 mmol/l
MgCl2, pH 9.0); either 2 μL BigDye® v1.1 (Life Technolo-
gies, Applied Biosystems) for forward sequencing reactions,
or 1.5 μL BigDye® v1.1 and 0.5 μL dGTP BigDye® v1.1 (Life
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reactions; 2 μL sequencing primer at 10 μM; and 2 μL PCR
product for a total reaction volume of 20 μL. Thermal
cycling conditions are as follows: 96°C hold for 1 minute,
followed by 25 cycles of 96°C for 15 seconds, 50°C for
5 seconds, and 60°C for 2 minutes.
For high-throughput sequencing of eleven amplified
samples at a time in our laboratory, all pipetting steps are
performed on a liquid-handling instrument (MICROLAB®
STARplus, Hamilton Robotics) using a master mix of
sequencing reagents and pre-made, single-use primer
plates. Sequencing reaction set-up is performed in two
sets: one set for the forward sequencing primers, and
the second set for the reverse sequences. To ensure
sufficient volume for instrument pipetting, sequencing
master mixes are prepared in 15 mL conical tubes
using 6958 μL deionized water, 5219 μL dilution buffer,
and 1740 μL BigDye® v1.1 (for forward sequencing;
1281 μL BigDye® v1.1 plus 427 μL dGTP BigDye® v1.1 is
used instead for reverse sequencing). Primer plates (also
prepared robotically) include 50 μL of each 10 μM primer
according to the plate layouts in Figure 9. Sequencing
plate maps (eight forward and eight reverse, for a total of
sixteen) for the described high-throughput process are
given in Figure 10.Sequence product purification
Sequence product purification is performed via gel filtra-
tion. For our high-throughput process, Performa DTR V3
96-well short plates (Edge Biosystems, Gaithersburg, MD)
are used, and purification steps are performed in two
eight-plate batches. Performa plates are first manually
centrifuged at 850 g for two minutes to remove some
liquid, as per the manufacturer’s recommendation.
Subsequently, pipetting from the sequencing product
plates to the prepared Performa plates is performed
robotically, then filtration into new, barcoded 96-well
plates is accomplished by manual centrifugation for
5 minutes at 850 g.Sequence detection and analysis
Purified sequence products are evaporated by heated vac-
uum centrifugation then resuspended in 10 μL Hi-Di™
Formamide (Life Technologies, Applied Biosystems).
For our high-throughput process, sequence detection is
performed by capillary electrophoresis on a 3730 Genetic
Analyzer (Life Technologies, Applied Biosystems) using
a 50 cm array, the FastSeq instrument protocol (Fas-
tSeq50_POP7 run module) and the SeqAnalysis Fast
analysis protocol (Basecaller_3730POP7RR) with the
default instrument settings. Post-detection, raw signal
data is initially processed on the 3730 Genetic Analyzer
computer using Sequencing Analysis v5.3.1 (LifeTechnologies, Applied Biosystems) with the spacing pa-
rameters set to 12.0.
Trimming, assembly and review of the processed elec-
tropherograms is performed in Sequencher version 4.8 or
5.0 (Gene Codes Corporation, Ann Arbor, MI). Sequences
are aligned to the rCRS [22]. For our purposes, and in
accordance with current requirements for publication of
mtDNA data sets [31], at least two high-quality, high-
resolution sequences covering every mtGenome position
are required for development of a complete mtGenome
haplotype.
Notes on instrumentation
While we currently utilize Hamilton Robotics liquid
handling instruments (MICROLAB® STARlet and STAR-
plus) for pre and post-PCR pipetting, portions of the assay
development and developmental validation were performed
on a Tecan Genesis® 2000 workstation (Tecan Group Ltd.,
San Jose, CA). The described workflow could be imple-
mented on any fit for purpose liquid handling instruments,
and the plate layouts (such as those depicted in Figure 10
for sequencing) modified according to instrument set-up
and desired throughput.
Thermal cycling steps in this protocol have been per-
formed with equal success on a variety of 96-well machines
in our laboratory, including GeneAmp® PCR System
9700 and Veriti® instruments (Life Technologies, Applied
Biosystems), TRobot thermal cyclers (Biometra GmbH,
Goettingen, Germany), and PTC-0200 DNA Engine instru-
ments (MJ Research, Inc., Waltham, MA). The described
cycling parameters should thus be appropriate for im-
plementation on most thermal cyclers with little, if any,
optimization needed.
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